Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC with mitomycin-C after complete cytoreductive surgery for colon cancer peritoneal metastases
2019-004679-37Phase 4Active
- Sponsor
- Hospital Universitario de Fuenlabrada
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of mitomycin c in colon cancer and peritoneal carcinomatosis (PC) (2 arms), sponsored by Hospital Universitario de Fuenlabrada. Primary endpoint: Peritoneal recurrence-free survival. Started Apr 2024; status: active.
02
Drugs
mitomycin c
03
Conditions
colon cancerperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on 2019-004679-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004679-37.